Organisation paid for research Program year 2025 Source: CMS Open Payments

Wake Forest Univ Health Sciences

Neither a doctor nor a teaching hospital

Research payments

$1,817,270

222 payments

Through program year 2025, Wake Forest Univ Health Sciences is reported as receiving $1,817,270 in research payments, across 222 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $439,318 90
2024 Research $208,108 25
2023 Research $82,889 4
2022 Research $232,085 10
2021 Research $238,809 33
2020 Research $148,710 28
2019 Research $467,351 32

Breakdown

Who paid Research payments · program years 2019–2025
  1. Abbott Laboratories $614,328 100 payments
  2. AstraZeneca Pharmaceuticals LP $456,722 53 payments
  3. AstraZeneca AB $387,755 6 payments
  4. Jazz Pharmaceuticals Inc. $128,000 4 payments
  5. Alexion Pharmaceuticals, Inc. $86,858 4 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $48,920 25 payments
  7. GlaxoSmithKline, LLC. $41,786 19 payments
  8. Pfizer Inc. $25,238 5 payments
  9. AstraZeneca UK Limited $21,272 4 payments
  10. Silk Road Medical, Inc. $6,392 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. NCT06899776 --- Assessing Chest Pain Using Point-of-Care High-Sensitivity Troponin I in the Emergency Department $380,141 67 payments
  2. Research Study APOL1 and chronic kidney disase $155,242 1 payment
  3. Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in ED for setting for $140,448 1 payment
  4. A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects $136,500 1 payment
  5. An Open Label Study of JZP 458 in Patients With Acute Lymphoblastic Leukemia (All)/Lymphoblastic Lymphoma $128,000 4 payments
  6. A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. $83,769 2 payments
  7. An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF) Short Title DETERMINE-preserved Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with preserved ejection fraction $49,643 6 payments
  8. AMETHYST Congestive Heart Failure CHF Heart Failure Therapy Area Cardiovascular, Renal and Metabolism $45,679 5 payments
  9. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $39,642 4 payments
  10. REALIZE-K Phase IV, randomized, double-blind, placebo-controlled, parallel-group trial evaluating Sodium Zirconium Cyclosilicate (SZC) for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction, chronic kidney disease and receiving spironolactone $39,433 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record